The Impact of Sucrose Ingestion During Exercise on Liver and Muscle Glycogen Concentration.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02110836|
Recruitment Status : Completed
First Posted : April 10, 2014
Last Update Posted : August 7, 2015
Carbohydrate is stored in the body as glycogen, which is mainly found in the liver and muscle. During endurance exercise, muscle glycogen is used as fuel for the working muscles and liver glycogen is broken down to provide glucose to maintain blood glucose (sugar) levels. Both liver and muscle glycogen are important for the ability to perform intense/prolonged endurance exercise. Therefore, nutritional strategies which can maximise the availability of glycogen in muscle and liver can benefit endurance exercise capacity.
The carbohydrates typically found in sports drinks are glucose and sometimes fructose. If glucose only is ingested during exercise, then the maximum rate at which can be absorbed from the intestine into the blood stream is ~1 g/min. However, if different sources of carbohydrate (fructose) are used, which are absorbed through a different pathway, absorption of carbohydrate can be up to ~1.8 g/min. With more carbohydrate available as a fuel, this translates into an improvement in performance.
Sucrose is a naturally occurring sugar that is made up of a single glucose and single fructose molecule. Therefore, theoretically, this can use the two different pathways of absorption and also maximise carbohydrate delivery. It is not yet known however, what impact this has on our liver and muscle glycogen stores during exercise. Therefore the aim of this study is to assess whether sucrose ingestion influences liver and muscle glycogen depletion during endurance exercise.
|Condition or disease||Intervention/treatment||Phase|
|Liver and Muscle Glycogen Use During Exercise.||Dietary Supplement: Glucose ingestion Dietary Supplement: Sucrose ingestion||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||14 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Primary Purpose:||Basic Science|
|Study Start Date :||April 2014|
|Actual Primary Completion Date :||September 2014|
|Actual Study Completion Date :||April 2015|
Active Comparator: Glucose ingestion
Glucose ingestion during exercise at a rate of 1.8 g/min.
Dietary Supplement: Glucose ingestion
Glucose ingestion during exercise at 1.8 g/min
Experimental: Sucrose ingestion
Sucrose ingestion during exercise at a rate of 1.8 g/min.
Dietary Supplement: Sucrose ingestion
Sucrose ingestion during exercise at 1.8 g/min
- Change in liver glycogen concentration [ Time Frame: 3 hours ]The change in liver glycogen concentration will be determined pre-to-post 3 h of exercise using 13C magnetic resonance spectroscopy.
- Plasma glucose concentration. [ Time Frame: 3 hours ]Plasma glucose concentrations will be determined every 30 min during 3 h of exercise.
- Plasma lactate concentration [ Time Frame: 3 hours ]Plasma lactate concentrations will be determined every 30 min during 3 h of exercise.
- Plasma non-esterified fatty acid concentration [ Time Frame: 3 hours ]Plasma non-esterified fatty acid concentrations will be determined every 30 min during 3 h of exercise.
- Indirect calorimetry [ Time Frame: 3 hours ]Measurements of oxygen consumption, carbon dioxide production and respiratory exchange ratio through indirect calorimetry measured every 30 minutes during exercise.
- Muscle glycogen concentration [ Time Frame: 3 hours ]The change in muscle glycogen concentration will be determined pre-to-post 3 h of exercise using 13C magnetic resonance spectroscopy.
- Change in intramyocellular lipid concentration [ Time Frame: 3 hours ]The change in intramyocellular lipid concentration will be determined pre-to-post 3 h of exercise using 1H magnetic resonance spectroscopy.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02110836
|Newcastle upon Tyne, Tyne and Wear, United Kingdom, NE1 8ST|
|Principal Investigator:||Luc van Loon, PhD||Maastricht University|